Skip to main content
. Author manuscript; available in PMC: 2015 Feb 11.
Published in final edited form as: Cancer. 2010 Oct 19;117(5):982–991. doi: 10.1002/cncr.25533

Figure 1.

Figure 1

Survival outcomes are shown according to erythropoietic-stimulating agent (ESA) use: (A) event-free survival (EFS) in early chronic phase patients; (B) overall survival (OS) in early chronic phase patients; (C) EFS in late chronic phase patients; (D) OS in late chronic phase patients.